Isoflurane description, usages, side effects, indications, overdosage, supplying and lots more!

Menu
Search

Isoflurane

RxElite Holdings Inc.
Piramal Healthcare Limited

Isoflurane, USP   Inhalation Anesthetic For Veterinary Use in Horses and Dogs  


FULL PRESCRIBING INFORMATION: CONTENTS*




FULL PRESCRIBING INFORMATION

BOXED WARNING


Not for use in horses intended for food

ISOFLURANE DESCRIPTION




Isoflurane

Each mL contains 99.9% Isoflurane.

Some physical constants are:

Molecular weight 184.5

Boiling point at 760 mm Hg    48.5°C (uncorr.)

Refractive index n 20 D            1.2990 - 1.3005

Specific gravity 25°/25°C        1.496

Vapor pressure in mm Hg**

            20°C     238

            25°C    295

            30°C    367

            35°C    450

**Equation for vapor pressure calculation:


10vapB

                                        T = °C+273.16 (Kelvin)

Partition coefficients at 37°C

            Water/gas       0.61

            Blood/gas         1.43

            Oil/gas             90.8

Partition coefficients at 25°C - rubber and plastic:

            Conductive rubber/gas     62.0

            Butyl rubber/gas             75.0

            Polyvinyl chloride/gas      110.0

            Polyethylene/gas             ~2.0

            Polyurethane/gas             ~1.4

            Polyolefin/gas                  ~1.1

           Butyl acetate/gas             ~2.5



Lower limit of flammability in oxygen or nitrous oxide at

9 joules/sec. and 23°C             None

Lower limit of                  Greater than

flammability in                  useful

oxygen or nitrous             concentration in

oxide at 900 joules/sec.    anesthesia.

and 23°C.

 MAC (Minimum Alveolar Concentration) is 1.31% in horses1 and 1.28% in dogs.6

Isoflurane is a clear, colorless stable liquid containing no additives or chemical stabilizers. Isoflurane has a mildly pungent, musty, ethereal odor. Samples stored in indirect sunlight in clear, colorless glass for five years, as well as samples directly exposed for 30 hours to a 2 amp, 115 volt, 60 cycle long wave U.V. light were unchanged in composition as determined by gas chromatography. Isoflurane in one normal sodium methoxide-methanol solution, a strong base, for over six months consumed essentially no alkali, indicative of strong base stability. Isoflurane does not decompose in the presence of soda lime (at normal operating temperatures), and does not attack aluminum, tin, brass, iron or copper.



CLINICAL PHARMACOLOGY


2,5

3,6

Blood pressure decreases with induction of anesthesia but returns toward normal with surgical stimulation. Progressive increases in depth of anesthesia produce corresponding decreases in blood pressure; however, heart rhythm is stable and cardiac output is maintained with controlled ventilation and normal PaCO2 despite increasing depth of anesthesia. The hypercapnia which attends spontaneous ventilation during isoflurane anesthesia increases heart rate and raises cardiac output above levels observed with controlled ventilation.3 Isoflurane does not sensitize the myocardium to exogenously administered epinephrine in the dog.

Muscle relaxation may be adequate for intraabdominal operations at normal levels of anesthesia. However, if muscle relaxants are used to achieve greater relaxation, it should be noted that: ALL COMMONLY USED MUSCLE RELAXANTS ARE MARKEDLY POTENTIATED WITH ISOFLURANE, THE EFFECT BEING MOST PROFOUND WITH THE NONDEPOLARIZING TYPE. Neostigmine reverses the effect of nondepolarizing muscle relaxants in the presence of isoflurane but does not reverse the direct neuromuscular depression of isoflurane.

INDICATIONS & USAGE


Isoflurane, USP is used for induction and maintenance of general anesthesia in horses and dogs.

ISOFLURANE CONTRAINDICATIONS


Isoflurane, USP is contraindicated in horses and dogs with known sensitivity to isoflurane or to other halogenated agents.

WARNINGS


Increasing depth of anesthesia with Isoflurane, USP may increase hypotension and respiratory depression. The electroencephalographic pattern associated with deep anesthesia is characterized by burst suppression, spiking, and isoelectric periods.4 Since levels of anesthesia may be altered easily and rapidly, only vaporizers producing predictable percentage concentrations of isoflurane should be used (see DOSAGE AND ADMINISTRATION).

 

The action of nondepolarizing relaxants is augmented by isoflurane. Less than the usual amounts of these drugs should be used. If the usual amounts of nondepolarizing relaxants are given, the time for recovery from myoneural blockade will be longer in the presence of isoflurane than in the presence of other commonly used anesthetics.

Not for use in horses intended for food.

 

PRECAUTIONS


Isoflurane, USP, like other inhalational anesthetics, can react with desiccated carbon dioxide (CO2) absorbents to produce carbon monoxide which may result in elevated carboxyhemoglobin levels in some patients. Case reports suggest that barium hydroxide lime and soda lime become desiccated when fresh gases are passed through the CO2 absorber canister at high flow rates over many hours or days. When a clinician suspects that CO2 absorbent may be desiccated, it should be replaced before the administration of Isoflurane, USP.

Usage in Pregnancy: Reproduction studies have been performed in mice and rats with no evidence of fetal malformation attributable to isoflurane. Adequate data concerning the safe use of isoflurane in pregnant and breeding horses and dogs have not been obtained.

General Precautions


Federal law restricts this drug to use by or on the order of a licensed veterinarian.

ISOFLURANE ADVERSE REACTIONS


Hypotension, respiratory depression and arrhythmias have been reported.

OVERDOSAGE



Stop drug administration, establish that the airway is clear and initiate assisted or controlled ventilation with pure oxygen as circumstances dictate.

DOSAGE & ADMINISTRATION

Caution: Operating rooms should be provided with adequate ventilation to prevent the accumulation of anesthetic vapors.

 

Premedication: A premedication regimen, which may be employed depending upon the patient status, to avert excitement during induction, might include an anticholinergic, a tranquilizer, a muscle relaxant, and a short-acting barbiturate.

 

Inspired Concentration: The delivered concentration of Isoflurane, USP should be known. Isoflurane may be vaporized using a flow-through vaporizer specifically calibrated for Isoflurane. Vaporizers delivering a saturated vapor which is then diluted (e.g., Vernitrol® vaporizer) also may be used. The delivered concentration from such a vaporizer may be calculated using the formula:


100PvFv
TAV

where: PA = Pressure of atmosphere

            PV = Vapor pressure of isoflurane

            FV=Flow of gas through vaporizer (mL/min)

            FT = Total gas flow (mL/min)

Isoflurane contains no stabilizer. Nothing in the drug product alters calibration or operation of these vaporizers.

 

Induction:

Horses: Inspired concentrations of 3.0 to 5.0% isoflurane alone with oxygen following a barbiturate anesthetic induction are usually employed to induce surgical anesthesia in the horse.

Dogs: Inspired concentrations of 2.0 to 2.5% isoflurane alone with oxygen following a barbiturate anesthetic induction are usually employed to induce surgical anesthesia in the dog.

These concentrations can be expected to produce surgical anesthesia in 5 to 10 minutes.

 

Maintenance: The concentration of vapor necessary to maintain anesthesia is much less than that required to induce it.

Horses: Surgical levels of anesthesia in the horse may be sustained with a 1.5 to 1.8% concentration of isoflurane in oxygen.

 

Dogs: Surgical levels of anesthesia in the dog may be sustained with a 1.5 to 1.8% concentration of isoflurane in oxygen.

The level of blood pressure during maintenance is an inverse function of isoflurane concentration in the absence of other complicating problems. Excessive decreases, unless related to hypovolemia, may be due to depth of anesthesia and in such instances may be corrected by lightening the level of anesthesia.

Recovery from Isoflurane is typically uneventful.2

HOW SUPPLIED


Isoflurane USP is packaged in 250mL (NDC 66794-013-25) and 100mL (NDC 66794-013-10) amber-colored bottles.

STORAGE


oooo

REFERENCES


1          Steffey, E.P., Howland, D.Jr., Giri, S. and Eger, E.I. II.:

            Enflurane, Halothane and Isoflurane Potency in Horses.

            Am. J. Vet. Res. 38(7): 1037-1039, 1977.

 

2          Auer, J.A., Garner, H.E., Amend, J.F.,             Hutcheson, D.P. and Salem, C.A.:

            Recovery from Anesthesia in Ponies: A Comparative Study of the Effects of Isoflurane, Enflurane, Methoxyflurane and Halothane.

            Equine Vet. J. 10(1): 18-23, 1978.

 

3          Steffey, E.P., and Howland, D.Jr.: Comparison of Circulatory and Respiratory Effects of Isoflurane and Halothane Anesthesia in Horses.

            Am. J. Vet. Res.: 41(5): 821-825, 1980.

 

4          Auer, J.A., Amend, J.F., Garner, H.E., Hutcheson, D.P. and Salem, C.A.:

            Electroencephalographic Responses During Volatile Anesthesia in Domestic Ponies: A Comparative Study of Isoflurane, Enflurane, Methoxyflurane and Halothane.

            Equine Practice 3: 130-134, 1979.

 

5          Klide, A.M.:

            Cardiopulmonary Effects of Enflurane and Isoflurane in the Dog.

            Am. J. Vet. Res.: Vol. 37, No. 2: 127-131, 1976.

 

6          Steffey, E.P., Howland, D.:

            Isoflurane Potency in the Dog and Cat.

            Am. J. Vet. Res.: Vol. 38, No. 11: 1833-1836, 1977.

Distributed by:
RxElite Holdings Inc,
172 South Academy Avenue,
Suite 150, Eagle, ID 83616
(888) 822-8431

Isoflurane

Isoflurane INHALANT

Product Information

Product Type Prescription animal drug label Item Code (Source) NDC:66794-013
Route of Administration RESPIRATORY (INHALATION) DEA Schedule

Active Ingredient/Active Moiety

Ingredient Name Basis of Strength Strength
ISOFLURANE ISOFLURANE 99.9 mL

Packaging

# Item Code Package Description Marketing Start Date Marketing End Date
1 NDC:66794-013-10 100 in 1 BOTTLE, GLASS
2 NDC:66794-013-25 250 in 1 BOTTLE, GLASS

Marketing Information

Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
ANADA ANADA200237 2009-07-28


PLEASE, BE CAREFUL!
Be sure to consult your doctor before taking any medication!
Copyright © 2014. drugs-library.com. All rights reserved. Information on drugs-library.com is provided for educational purposes only and is not to be used for medical advice, diagnosis or treatment.
Support info@drugs-library.com.